Therapeutic Development in Amyotrophic Lateral Sclerosis
- 1 March 2015
- journal article
- review article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 37 (3), 668-680
- https://doi.org/10.1016/j.clinthera.2014.12.020
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- The past, present and future of stem cell clinical trials for ALSExperimental Neurology, 2014
- The murky path to drug discovery in ALS becomes clearerThe Lancet Neurology, 2013
- Mitochondrial Diseases of the BrainFree Radical Biology & Medicine, 2013
- Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trialThe Lancet Neurology, 2013
- Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiencyBrain Research, 2012
- Molecular pathways of motor neuron injury in amyotrophic lateral sclerosisNature Reviews Neurology, 2011
- Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALSNeuron, 2011
- Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activityProgress in Neurobiology, 2010
- Neuroinflammation in Parkinson's disease: a target for neuroprotection?The Lancet Neurology, 2009
- Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse modelZeitschrift für Neurologie, 2004